Intelligence Feed event · Equity · 2026-09-09

    Dentsply Sirona Tops Q2 EPS at $0.52 and Affirms Full-Year $3.5B-$3.6B Sales Guidance

    Question

    Dentsply Sirona Tops Q2 EPS at $0.52 and Affirms Full-Year $3.5B-$3.6B Sales Guidance

    Direct answer

    Dentsply Sirona reported Q2 adjusted EPS of $0.52, beating consensus of $0.36 despite a 4.1% year-over-year decline in total net revenue. Operating performance was anchored by the Wellspect Healthcare division, which grew 7.1%. Management reaffirmed its full-year 2026 outlook, guiding to net sales of $3.5 billion to $3.6 billion and adjusted EPS between $1.40 and $1.50, demonstrating cost containment amidst mixed equipment demand.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Dentsply Sirona Tops Q2 EPS at $0.52 and Affirms Full-Year $3.5B-$3.6B Sales Guidance”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/dentsply-sirona-tops-q2-eps-at-0-52-and-affirms-full-year-3-5b-3-6b-sales-guidan-86492c

    EQUITY
    Dentsply Sirona Tops Q2 EPS at $0.52 and Affirms Full-Year $3.5B-$3.6B Sales Guidance
    Dentsply Sirona reported Q2 adjusted EPS of $0.52, beating consensus of $0.36 despite a 4.1% year-over-year decline in total net revenue. Operating performance was anchored by the Wellspect Healthcare division, which grew 7.1%. Management reaffirmed its full-year 2026 outlook, guiding to net sales of $3.5 billion to $3.6 billion and adjusted EPS between $1.40 and $1.50, demonstrating cost containment amidst mixed equipment demand.
    XRAY
    Impact
    67
    SEP 9
    SIG
    88%
    XRAY
    Dentsply Sirona Tops Q2 EPS at $0.52 and Affirms Full-Year $3.5B-$3.6B Sales Guidance
    Dentsply Sirona reported Q2 adjusted EPS of $0.52, beating consensus of $0.36 despite a 4.1% year-over-year decline in total net revenue. Operating performance was anchored by the Wellspect Healthcare division, which grew 7.1%. Management reaffirmed its full-year 2026 outlook, guiding to net sales of $3.5 billion to $3.6 billion and adjusted EPS between $1.40 and $1.50, demonstrating cost containment amidst mixed equipment demand.
    → Margin expansion in Wellspect Healthcare offsets top-line equipment contraction to protect XRAY's FY2026 free cash flow trajectory.
    Impact
    Dentsply Sirona reported Q2 adjusted EPS of $0.52, beating consensus of $0.36 despite a 4.1% year-over-year decline in total net revenue. Operating performance was anchored by the Wellspect Healthcare division, which grew 7.1%. Management reaffirmed its full-year 2026 outlook, guiding to net sales of $3.5 billion to $3.6 billion and adjusted EPS between $1.40 and $1.50, demonstrating cost containment amidst mixed equipment demand.
    Affected
    XRAY
    Transmission
    Margin expansion in Wellspect Healthcare offsets top-line equipment contraction to protect XRAY's FY2026 free cash flow trajectory.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    XRAYoperating margin resilience supporting FY2026 EPS guidance floorUp1-5dAdjusted EPS of 52 cents versus 36 cents consensus, maintaining full-year 2026 guidance.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XRAYUpdisagreed10.72 2026-09-09-2.05%-5.41%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month